Lonza has expanded its mammalian production capacity at its Slough (UK) facility. Two 1000-L single-use bioreactors will be installed at the site. This expansion will increase the existing single-use manufacturing capacity in Slough while allowing current operations to continue without interruption. The additional mammalian manufacturing capacity is now available.

Lonza's cGMP facility in Slough is the center of excellence for development and clinical supply. The site provides cell-line construction, process development, and clinical manufacturing services for mammalian-derived biotherapeutics.

The increase in bioreactor capacity continues the implementation of single-use technologies at the Slough site and complements existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations. The new reactors are equipped with controllers that enable parallel reactor operations, expanded process capabilities with flexible operating scales, and bioreactor types. Use of these technologies supports Lonza's ability to accommodate a variety of customer projects and processes across scales and clinical phases, according to the company.

Source: Lonza